Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235).
(25/60)
(+info)
An ADIOL-ERbeta-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.
(26/60)
(+info)
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.
(27/60)
(+info)
Beta androstenediol mitigates the damage of 1 GeV/n Fe ion particle radiation to the hematopoietic system.
(28/60)
(+info)
Metabolic alteration of urinary steroids in pre- and post-menopausal women, and men with papillary thyroid carcinoma.
(29/60)
(+info)
Adrenal androgens and the menopausal transition.
(30/60)
(+info)
Androstenediol complements estrogenic bioactivity during the menopausal transition.
(31/60)
(+info)
Menopausal transition stage-specific changes in circulating adrenal androgens.
(32/60)
(+info)